Clinical trial
Regorafenib in Frail and/or Unfit for Chemotherapy Patients With Metastatic Colorectal Cancer (REFRAME)
The purpose of this study is to assess the efficacy and safety of single-agent regorafenib in the first line treatment of frail and/or unfit for polychemotherapy patients with metastatic colorectal cancer (mCRC)